Kidney Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Treated with Long-term Lumasiran

Sunday, April 27, 2025

2:30pm – 2:45pm HST

Location: Convention Center: 316 A

Michael Somers, Boston Children's Hospital, Boston, MA, United States; Arnaud Devresse, Cliniques universitaires Saint-Luc, Brussels, Brussels Hoofdstedelijk Gewest, Belgium; Richard Willey, Alnylam Pharmaceuticals, High Bridge, NJ, United States; Desmond Murphy, Alnylam Pharmaceuticals, Boston, MA, United States; Anne-Laure Sellier-Leclerc, Children's Hospital, Lyon, Rhone-Alpes, France; Cristin Kaspar, Alnylam Pharmaceuticals, Cambridge, MA, United States; Justine Bacchetta, Hospices Civils de Lyon & INSERM1033, bron, Rhone-Alpes, France

Presenting Author(s)

Michael Somers, MD
Associate Chief, Division of Nephrology
Boston Children's Hospital
Boston, Massachusetts, United States

Disclosure(s):

Michael Somers, MD: Alnylam Pharmaceuticals (Ongoing) (Products/Services: Consultant); Dicerna Pharmaceuticals (Ongoing) (Products/Services: Consultant); Novo Nordisk (Ongoing) (Products/Services: Advisory Committee)